Targeting imet on genetic subtypes: hope for effectiveness?

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Posts: 144
Joined: Sun Apr 03, 2016 11:27 pm

Targeting imet on genetic subtypes: hope for effectiveness?

Post by cheng_ho » Sun Feb 09, 2020 2:47 pm

Just as Gleevec got its reputation because it is only used on genetic subtypes where it has a better chance, Imetelstat might be developed into an effective therapy if susceptible subtypes are found. (Caffeine is actually VERY effective on cancers with a certain DNA-repair defect...)

Hayflick on the YHOO board brought up WIPO patent wo2020028261 (2020-02-06), which details which MF patients will benefit most from imet.

This is the kind of breakthrough that might (if the effectiveness is high enough) actually be a game-changer in getting AA in MF.

(Of course a FAR bigger breakthrough would be sequencing cancer DNA to find vulnerabilities to caffeine, Vitamin C, and other low-toxicity molecules... but the patent/FDA system prevents that from happening inside the US. No way to fund it).

Post Reply